Physician profile
Daniel Alan Sherman
NPI 1093375867
$349.38
in general payments reported to CMS, 2019-2025
12 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.25 · 2021: $30.94 · 2022: $87.36 · 2024: $79.40 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $87.36 | 2022 | |
| Collegium Pharmaceutical, INC. | $40.20 | 2025 | Jornay Pm |
| Corium, LLC | $39.04 | 2025 | Azstarys |
| Ucb, INC. | $30.94 | 2021 | |
| Cranial Technologies, INC | $29.88 | 2024 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $20.74 | 2024 | Flumist Quadrivalent |
| Tris Pharma INC | $20.39 | 2025 | Dyanavel Xr |
| Pfizer INC. | $18.25 | 2019 | |
| Glaxosmithkline, LLC. | $17.00 | 2025 | Pediarix, Bexsero |
| Sanofi-Aventis U.S. LLC | $16.80 | 2025 | |
| Neos Therapeutics, LP | $15.59 | 2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $13.19 | 2024 | Vaxelis, Vaqta, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.